Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an interventional, non-randomized, open-label study. Brain tumor samples will be
collected from patients for organoids generation and subject to panel drugs screening and
QPOP analysis to derive the optimal drug combinations for treatment at the time of first high
grade astrocytic glioma recurrence. The investigators hypothesize that patient-derived
organoids (PDOs) mimic the biological characteristics of high grade astrocytic gliomas and
serve as an ideal platform for the evaluation of drug sensitivities, accurately reflecting
the patient's therapeutic response to the drugs.